SIRP-β1b Activators
SIRP-β1b Activators comprise a diverse array of chemical compounds that indirectly enhance the functional activity of SIRP-β1b by modulating immune signaling pathways, particularly in cells like macrophages and dendritic cells where SIRP-β1b is prominently expressed. Compounds such as Anakinra, which is an IL-1 receptor antagonist, contribute to this enhancement by altering the cytokine signaling landscape, thereby affecting phagocytic and immune signaling pathways in which SIRP-β1b is involved. Toll-like receptor (TLR) agonists play a significant role in this modulation: Monophosphoryl Lipid A (MPL), Poly(I:C), CpG Oligodeoxynucleotide, Lipopolysaccharide (LPS), Resiquimod, Imiquimod, R848, Gardiquimod, Zymosan, Pam3CSK4, and Flagellin, each targeting different TLRs, activate respective TLR signaling pathways. This activation enhances SIRP-β1b's activity by stimulating immune responses and influencing the signaling network in immune cells, thereby modulating SIRP-β1b's role in immune regulation and cell signaling.
These activators, by engaging various TLR pathways, facilitate a broad spectrum of immune responses, thereby impacting SIRP-β1b's functionality in a multifaceted manner. For instance, LPS and MPL, as TLR4 agonists, and Poly(I:C), a TLR3 agonist, enhance SIRP-β1b's role in dendritic cell and macrophage signaling, crucial for effective immune surveillance and response. Similarly, TLR7/8 agonists like Resiquimod, Imiquimod, R848, and Gardiquimod, and TLR2 agonist Zymosan, by modulating dendritic cell and macrophage functions, indirectly enhance SIRP-β1b's activity in phagocytic and immune regulatory processes. Furthermore, Flagellin, as a TLR5 agonist, adds another layer of modulation to SIRP-β1b's activity in immune cell signaling. Collectively, these SIRP-β1b Activators, through their targeted effects on key immune signaling pathways, particularly TLR signaling, facilitate the enhancement of SIRP-β1b-mediated functions in immune regulation and cellular communication, integral to the innate and adaptive immune responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
Anakinra, an IL-1 receptor antagonist, can indirectly enhance SIRP-β1b activity by modulating immune responses, particularly those involving macrophages and dendritic cells where SIRP-β1b is expressed, affecting phagocytic signaling pathways. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
MPL, a Toll-like receptor 4 (TLR4) agonist, activates TLR4 signaling, which can influence the activity of SIRP-β1b by modulating the immune cell signaling network, particularly in dendritic cells and macrophages. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
Poly(I:C), a synthetic analog of double-stranded RNA, activates TLR3 signaling. This activation can enhance SIRP-β1b activity by stimulating immune responses in cells where SIRP-β1b is involved, such as dendritic cells. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
LPS, a TLR4 ligand, activates TLR4 signaling pathways, potentially enhancing SIRP-β1b activity by influencing macrophage and dendritic cell functions where SIRP-β1b is involved in immune cell signaling. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod, another TLR7 agonist, activates TLR7 signaling, potentially enhancing SIRP-β1b activity by modulating the immune response in cells expressing SIRP-β1b, like dendritic cells. | ||||||
CGS 21680 Hydrochloride | 124431-80-7 | sc-211062 sc-211062A | 10 mg 50 mg | $292.00 $1044.00 | 7 | |
R848, which activates TLR7/8, can indirectly enhance SIRP-β1b activity by influencing TLR7/8-mediated signaling pathways in immune cells, particularly where SIRP-β1b plays a role in immune regulation. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
Gardiquimod, a TLR7 agonist, enhances SIRP-β1b activity by activating TLR7 signaling, influencing immune responses in cells expressing SIRP-β1b, such as in dendritic cells and macrophages. | ||||||
Zymosan | 9010-72-4 | sc-296863 sc-296863A | 100 mg 1 g | $99.00 $599.00 | 1 | |
Zymosan, a TLR2 agonist, activates TLR2 signaling, potentially enhancing SIRP-β1b activity by modulating immune responses in macrophages and dendritic cells, where SIRP-β1b is involved in phagocytic signaling. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
Pam3CSK4, a synthetic triacylated lipopeptide and TLR1/2 agonist, activates TLR1/2 signaling, potentially enhancing SIRP-β1b activity by influencing the immune response in cells expressing SIRP-β1b. | ||||||